Elxaban close by $24 million in June prescription amount
Lixiana is at the head of the NOAC market
While Liquisia (Chong Kun Dang Pharm.) is in the lead of Eliquis’ generic market, Elxaban (Samjin Pharm) is catching up.
According to the recent trend of the outpatient report, Liquisia is at the top of Eliquis generic with an overwhelming gap by achieving $900 million in prescription costs.
With the $24 million gaps with Liqusia ($193 million), Elxaban made $169 million in prescription costs.
Elxaban and Yuhan Apixaban (Yuhan Corp.) also joined the leading group by reaching their semi-annual prescription cost by $573 million and $500 million in June.
Apixban (Hanmi Pharm.) achieved prescription performance about $300 million, followed by Eliban (Aju Pharm.) and Yupix (Yooyoung Pharm.) $200 million, and Apiquis (Huons) and Antixaban (Hutecs) $100 million.
Meanwhile, Lixiana (Daiichisankyo) maintained the lead in the NOAC market by having $31.7 billion in the first half of last year and $30.0 billion range in the second half of the last year.
In IQVIA data, although Lixiana has slowed down since the opening of the Eliquis generic market, it has continued to lead the way in the outpatient prescription analysis.
Follow by Lixiana, Xarelto (Bayer) grew backward from the same period of last year by carrying out $24.8 billion, but Eliquis is chasing Xarelto by $300 million with $24.4 billion.
Pradaxa’s (Boehringer Ingelheim) was reduced to $7.4 billion with more than 20% degrowth.
